Defined-Weight Recombinant Collagen Peptides for Tissue Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for agents and methods that can effectively treat and maintain connective tissue health, particularly in skin, tendons, ligaments, cartilage, and bones, while avoiding the disadvantages of collagen hydrolysates derived from animal materials, such as contamination concerns and complex manufacturing processes.
Innovation Solution
Development of synthetic or recombinant collagen peptides with defined molecular weights between 0.18 to 5.0 kDa, capable of stimulating the synthesis of extracellular matrix proteins in connective tissue cells, specifically designed with amino acid sequences selected from SEQ ID Nos. 1 to 30, which can be produced in a standardized, reliable, and cost-effective manner.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If collagen hydrolysates are derived from animal materials, then biological activity and therapeutic efficacy are achieved, but contamination risks and complex manufacturing processes increase
Solution Approach 1:
The patent creates synthetic and recombinant copies of natural collagen peptides with identical or optimized amino acid sequences. These synthetic peptides replicate the biological activity of animal-derived collagen while eliminating contamination risks from biological sources. The copying principle is applied by using computational design and synthetic biology to produce peptide sequences that mirror natural collagen's therapeutic effects without requiring animal materials.
Solution Approach 2:
The patent replaces complex enzymatic hydrolysis processes with direct chemical synthesis and recombinant production methods. Instead of using enzymes to break down animal collagen into peptides (mechanical/biological system), the invention uses controlled chemical synthesis or recombinant DNA technology to directly produce the desired peptide sequences, simplifying manufacturing and eliminating contamination from enzymatic processes and animal sources.
2Reliability
If collagen hydrolysates are derived from animal materials, then biological activity is achieved, but manufacturing complexity and cost increase
Solution Approach 1:
The patent creates synthetic and recombinant copies of natural collagen peptides with identical or optimized amino acid sequences. These synthetic peptides replicate the biological activity of animal-derived collagen while eliminating contamination risks from biological sources. The copying principle is applied by using computational design and synthetic biology to produce peptide sequences that mirror natural collagen's therapeutic effects without requiring animal materials.
Solution Approach 2:
The patent replaces complex enzymatic hydrolysis processes with direct chemical synthesis and recombinant production methods. Instead of using enzymes to break down animal collagen into peptides (mechanical/biological system), the invention uses controlled chemical synthesis or recombinant DNA technology to directly produce the desired peptide sequences, simplifying manufacturing and eliminating contamination from enzymatic processes and animal sources.
3Reliability
If collagen peptides with specific molecular weights are used, then therapeutic efficacy is improved, but production precision requirements increase
Solution Approach 1:
The patent segments the collagen molecule into specific peptide fragments with defined molecular weights and amino acid sequences. By identifying and producing only the bioactive segments of collagen (specific peptides rather than whole collagen or broad hydrolysates), the invention achieves precise molecular weight control. This segmentation allows for targeted production of peptides with optimal therapeutic properties while simplifying purification and quality control.
Solution Approach 2:
The patent systematically varies peptide parameters including molecular weight, amino acid sequence, and post-translational modifications to optimize therapeutic efficacy. By controlling these parameters during synthesis and selection, the invention identifies peptide specifications that maximize biological activity while establishing clear manufacturing targets for molecular weight control, reducing the complexity of precision requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant collagen peptides exhibit biological activity in connective tissues, effectively treating conditions like osteoarthritis, osteoporosis, and improving skin health, with efficacy comparable to or exceeding that of naturally derived peptides, and can be produced without the drawbacks of animal-derived sources.
Implementation Method 1
capable of stimulating the synthesis of extracellular matrix proteins in connective tissue cells
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3
AI summary
The invention relates to a synthetic or recombinant collagen peptide for use in a method for the treatment of the human or animal body by therapy, the peptide having a molecular weight in a range of 0.18 to 10.0 kDa, particularly 0.18 to 5.0 kDa, more particularly 1.0 to 5.0 kDa. The invention also relates to products comprising the collagen peptide according to the invention and to methods for producing the collagen peptide according to the invention.